TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Intragastric pressure during food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Transfusion strategy effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opiate-negative urine screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sore Throat Pain Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of times intraprocedural heat therapy is used to achieve haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from atrial tachyarrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Obstructive Sleep Apnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of self-selection population who make a correct selection decision regarding use of the product
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Active Use Study Days on which a subject reported taking the product
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of subjects who are adherent to daily dosing instructions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase of serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Tinetti Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic uptake and washout of 123-I AV151
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence or absence of genetic polymorphisms in the histamine pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aldosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in the AUDIT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the DAST
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the AADIS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variation from baseline of MRI radiological semiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent Change From Baseline in Esophageal Peak Eosinophil Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change From Baseline in Pain Score During Week 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Pain Score During Week 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of progression-free interval
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and duration of objective response as assessed on radiologic scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative patient survival
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in anticoagulation treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acute kidney injury diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Positive and Negative Affect Schedule (PANAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in Peak Oxygen Consumption (Vo2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Work Performed During a Maximal-effort Exercise Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression from SMM to MM
Endpoint domain: Mortality/survival
Primary endpoint: All Incidences of Erythema
Endpoint domain: Adverse events/effects
Primary endpoint: CLA intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Curve (AUC) of Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With ASAS 40 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability measured by Expanded Disability Status Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness of perioperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ESSPRI Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with adverse events as a measure of safety
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events as a measure of tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Increased baseline creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: percentage of identified patients with stroke/TIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Joint Damage Assessment (JADI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Accuracy of 3D ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lift of lax tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elderly's physical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid peroxides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reactive oxygen species (ROS) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in urinary voids per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of adverse events during the 8-week telerehabilitation program
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Pressure (Diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Pressure (Mean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The Number of Hospitalizations for Diarrhea in Children up to 5 Years of Age
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: The Percentage of Hospitalizations for Diarrhea in Children up to 5 Years of Age
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: The Number of Deaths in Hospitalized Participants Enrolled in the Study
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative Number of Newly Gadolinium-enhancing Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete antiemetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve (AUC) 0 to 4 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time When Maximum Plasma Concentration Was Observed (Tmax) 0 to 4 Hours Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Maximum Plasma Concentration (Cmax) From Time 0 (Dosing) to 4 Hours Post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on fluid resuscitation effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Abnormal Electrocardiogram (ECG) Findings Reported as TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Augmentation Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of two or more home visits from an FLW in the final trimester of pregnancy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Delivery at a facility (versus home birth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of Breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: khat use quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days with khat use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Plasma Concentration-time Curve From Zero to the Time of Last Measurable Concentration [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penn State Worry Questionnaire (PSWQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in Number and Relative Frequency of Severe Adverse Events (SAE) and Non Severe Adverse Events (nSAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerance to Peanut Oral Food Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Level Self Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Subjects With Anti-Polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 1.0 µg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-rotavirus Serum Immunoglobulin A (IgA) Geometric Mean Concentrations (GMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Anti-Hepatitis A (Anti-Havrix) Antibody Concentrations ≥ 15mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Humphrey visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the frequency of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had at Least One Follicle Greater Than 17mm in Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants With E2 Level in Blood Serum Above 109 pg/mL on the Day of hCG Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Limb Volume Change (ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb Volume Change (Percent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily Combined Symptom and Medication Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of neointimal coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: TLC% predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life for Respiratory Illness Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of complications of liver cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with PASI75 at week 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with PGA0/1 at week 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in tumor hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Degree of scoliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional ability in daily life activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in respiratory variation of carotid artery blood flow peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients With Peripheral Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical longevity of restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conductivity measurements of effluent dialysate solutions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain level in laboring women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful self administration of romiplostim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with at least one episode of hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With No Visible Implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative excretion of radioactivity in urine and faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetic parameters of esreboxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with identified causal mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of biological samples collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Abnormal bone mineral density rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in plasma Vascular Endothelial Growth Factor (VEGF) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Relapse rate of atrial tachyarrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain assessed by Graded Chronic Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression assessed by Patient Health Questionnaire - 9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety assessed by Generalized Anxiety Disorder - 7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived stress assessed by Perceived Stress Scale - 10
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Migration of tibial component
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Topical Atopic Dermatitis Severity Index (toADSI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale for Pruritis (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with optimal alemtuzumab levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of mothers with HIV-1 isolates with new NNRTI resistance-associated mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects with plasma HIV-1 RNA < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse Events Recording
Endpoint domain: Adverse events/effects
Primary endpoint: Pulse/Heart Rate Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12-lead Electrocardiogram Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival from Death
Endpoint domain: Mortality/survival
Primary endpoint: Plasma Potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Comparison of ISR to FBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes on spinal excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient satisfaction with breast reconstruction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: early complication rate (bleeding, pain)
Endpoint domain: Adverse events/effects
Primary endpoint: long term outcome (symptomatic hemorrhoids recurrence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein expression pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rPFS rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with local and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects reporting one or more adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cognitive Flexibility - Condition 4 Trail Making Test of DKEFS
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Inhibition - Condition 3 of Color-Word Interference, DKEFS
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Self-Reported Shifting - BRIEF
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: serum level of neuroactive steroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Audit of Diabetes Dependent Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum tolerated dose determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best objective response evaluation of portal vein tumor thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of complete remission (CR) or complete remission with incomplete recovery of platelets (CRp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severe toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Alcohol and drug abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants in staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra abdominal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ECP treatment combined with corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of ECP treatment combined with corticosteroids
Endpoint domain: Adverse events/effects
Primary endpoint: number of identified positive or negative intraoperative SLN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Score on Treatment Self-Regulation Questionnaire (TSRQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pressure sensitivity (pain pressure threshold)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of 30 day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of 30 day readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of a prolonged length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Occurrence of venous thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduced blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total intraoperative fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Ocular Pain VAS Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Satisfied or Very Satisfied With Information Given to Them
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Successful Contacts With Families Via Telephone and/or in Clinic
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Symptoms and conditions of tongue and pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Percentage of Patients That Use Monitoring Device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: In-hospital direct costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Inadequate response to Human Recombinant Erythropoietin treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: prevalence of neurologic consequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: prevalence of orthopedic consequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: prevalence of pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: mean neurobehavioral scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Flow-mediated vasodilatation (FMD) difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes